Carol Lynch, president of Sandoz US and head of North America, discusses the promise of the US biosimilars market.
Transcript:
Do you think there is potential to increase biosimilar uptake in the United States?
I think that the promise of biosimilars is still there for the US market. I think the savings potential is enormous and the ability to expand access for patients to biologic medicines is tremendous. There are estimates out there that for every day, for example, a biosimilar etanercept is not available on [the] market that it’s actually costing millions of doctors.
We actually got approval for Erelzi in August of 2016 and yet we’re still not allowed to market this product because we’re in litigation and we can’t bring it to market until that court case has been resolved. At this rate, it looks like it will be around $3 billion of savings that have been missed, and for patients in the system and for the healthcare system as a whole, I think that’s something that we all need to take on.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.